___

• Kaya Z, Gursel T, Kocak U, Aral YZ, Kalkancı A, Albayrak M. Invasive fungal infections in pediatric leukemia patients receiving fluconazole prophylaxis. Pediatr Blood Cancer. 2009;52:470–5.
• Sung L, Gamis A, Alonzo TA, Buxton A, Britton K, Deswarte-Wallace J et al. Infections and association with different intensity of chemotherapy in children with acute myeloid leukemia. Cancer. 2009;115:1100–8.
• Creutzig U, Zimmermann M, Bourquin JP, Dworsak MN, Fleischhack G, von Neuhoff C et al. CNS irradiation in pediatric acute myleoid leukemia: equal results by 12 or 18 Gy in studies AML-BFM98 and 2004. Pediatr Blood Cancer. 2011;57:986–92.
• Abbott BL, Rubnitz JE, Tong X, Srivastana DK, Pui CH, Riberio RC et al. Clinical significance of central nervous system involvement at diagnosis of pediatric acute myeloid leukemia: a single institution’s experience. Leukemia. 2003;17:2090–6.
• Sievers EL, Lange BJ, Alonzo TA, Gerbing RB, Berstein ID, Smith FO et al. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children’s Cancer Group study of 252 patients with acute myeloid leukemia. Blood. 2003;101:3398–406.
• Port M, Böttcher M, Thol F, Ganser A, Schlenk R, Wasem J et al. Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis. Ann Hematol. 2014;93:1279–86.
• Johnston DL, Alonzo TA, Gerbing RB, Lange BJ, Woods WG. Superior outcome of pediatric acute myeloid leukemia patients with orbital and CNS myeloid sarcoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2012;58:519–24.
• Johnston DL, Alonzo TA, Gerbing RB, Lange BJ, Woods WG. The presence of central nervous system disease at diagnosis in pediatric acute myeloid leukemia does not affect survival: a Children’s Oncology Group study. Pediatr Blood Cancer. 2010;55:414–20.
• Johnston DL, Alonzo TA, Gerbing RB, Hirsch B, Heerema NA, Ravindranath Y et al. Outcome of pediatric patients with acute myeloid leukemia (AML) and -5/5q- abnormalities from five pediatric AML treatment protocols: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2013;60:2073–8.
• Harrison CJ, Hills RK, Moorman AV, Grimwade DJ, Hann I, Webb DK et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol. 2010;28:2674–81.
• Klusmann JH, Creutzig U, Zimmermann M, Dworzak M, Jorch N, Langebrake C et al. Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood 2008;111:2991-8.
• Lange BJ, Gerbing RB, Feusner J, Skolnik J, Sacks N, Smith FO et al. Mortality in overweight and underweight children with acute myeloid leukemia. JAMA. 2005;293:203–11.
• Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, Kremens B, Lehrnbecher T et al. Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report. Leukemia. 2012;26:654–61.
• Johansson B, Fioretos T, Kullendorff CM, Wiebe T, Bekassy AN, Garwicz S et al. Granulocytic sarcomas in body cavities in childhood acute myeloid leukemias with 11q23/MLL rearrangements. Genes Chromosomes Cancer. 2000;27:136-42.
• Sung L, Aplenc R, Alonzo TA, Gerbing RB, Gamis AS. Predictors and short-term outcomes of hyperleukocytosis in children with acute myeloid leukemia: a report from the Children’s Oncology Group. Haematologica. 2012;97:1770–3.
• Ganzel C, Becker J, Mintz PD, Lazarus HM, Rowe JM. Hyperleukocytosis, leukostasis and leukapheresis: practice management. Blood Rev. 2012;26:117–22.
• Sung L, Aplenc R, Alonzo TA, Gerbing RB, Gamis AS. Predictors and short-term outcomes of hyperleukocytosis in children with acute myeloid leukemia: a report from the Children’s Oncology Group. Haematologica. 2012;97:1770–3.
• Barbui T, Falanga A. Disseminated intravascular coagulation in acute leukemia. Semin Thromb Hemost. 2001;27:593–604.
• Arber DA, Vardiman JW, Brunning RD. Acute myeloid leukaemia with recurrent genetic abnormalities. In WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. (Eds SH Swerdlow, E Campo, NH Harris). Lyon, France, International Agency for Research on Cancer, 2008.
• Massey GV, Zipursky A, Chang MN, Doyle JJ, Nasim S, Taub JW et al. A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children’s Oncology Group (COG) study POG-9481. Blood. 2006;107:4606–13.
• Gamis AS, Alonzo TA, Gerbing RB, Hilden JM, Sorrel AD, Sharma M et al. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children’s Oncology Group study A2971. Blood. 2011;118:6752–79.
• Rabin KR, Whitlock JA. Malignancy in children with trisomy 21. Oncologist. 2009;14:164-73.
• Puumala SE, Ross JA, Aplenc R, Spector LG. Epidemiology of childhood acute myeloid leukemia. Pediatr Blood Cancer. 2013;60:728–33.
• Arceci RJ, Meshinchi S. Acute myeloid leukemia, myeloproliferative and myelodysplastic disorders. In Principles and Practice of Pediatric Oncology, 7th ed. (Eds PA Pizzo PA, DG Poplack): DG, Eds. Philadelphia: Lippincott Williams & Wilkins. 2015:498-544.